Nutanix demonstrates exceptional fundamental health with a Piotroski F-Score of 8/9, signaling strong operational efficiency and financial stability. While the stock is currently in a severe technical downtrend (0/100), the valuation is highly attractive on a growth-adjusted basis with a PEG ratio of 0.86 and a Forward P/E of 17.66. The company maintains elite gross margins of 87.13% and a remarkable track record of beating earnings estimates over 25 consecutive quarters. Despite trading above the growth-based intrinsic value of $28.32, the combination of earnings acceleration and analyst targets suggests a strong recovery potential.